How much revenue did MacroGenics generate this year?
MacroGenics has achieved a revenue of 123.71 M USD this year.
MacroGenics Revenue 2024
MacroGenics Revenue
123.71 M USD
Ticker
MGNX
ISIN
US5560991094
WKN
A1W6ND
In 2024, MacroGenics's sales reached 123.71 M USD, a 110.57% difference from the 58.75 M USD sales recorded in the previous year.
The MacroGenics Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 342.21 | 14,76 |
| 2028e | 164.14 | 30,78 |
| 2027e | 88.94 | 56,81 |
| 2026e | 94.25 | 53,61 |
| 2025e | 89.46 | 56,48 |
| 2024e | 123.71 | 40,84 |
| 2023 | 58.75 | 86,00 |
| 2022 | 151.9 | 95,19 |
| 2021 | 77.4 | 96,64 |
| 2020 | 104.9 | 48,17 |
| 2019 | 64.2 | 78,70 |
| 2018 | 60.1 | 84,07 |
| 2017 | 157.7 | 32,04 |
| 2016 | 91.9 | 54,98 |
| 2015 | 100.9 | 50,08 |
| 2014 | 47.8 | 105,71 |
| 2013 | 58 | 87,12 |
| 2012 | 63.8 | 79,20 |
| 2011 | 57.2 | 88,33 |
MacroGenics Revenue, EBIT, Net Income US5560991094 · A1W6ND
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into MacroGenics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MacroGenics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MacroGenics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of MacroGenics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into MacroGenics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing MacroGenics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MacroGenics’s growth potential.
MacroGenics Revenue, EBIT and net profit per share
| Date | MacroGenics Revenue | MacroGenics EBIT | MacroGenics Net Income |
|---|---|---|---|
| 2029e | 342.21 M undefined | 0 undefined | 13.43 M undefined |
| 2028e | 164.14 M undefined | -158.37 M undefined | -95.96 M undefined |
| 2027e | 88.94 M undefined | -239.63 M undefined | -109.4 M undefined |
| 2026e | 94.25 M undefined | -187.88 M undefined | -132.43 M undefined |
| 2025e | 89.46 M undefined | -169.75 M undefined | -162.91 M undefined |
| 2024e | 123.71 M undefined | -177.12 M undefined | -139.86 M undefined |
| 2023 | 58.75 M undefined | -168.24 M undefined | -9.06 M undefined |
| 2022 | 151.9 M undefined | -121.4 M undefined | -119.8 M undefined |
| 2021 | 77.4 M undefined | -202.8 M undefined | -202.1 M undefined |
| 2020 | 104.9 M undefined | -131.1 M undefined | -129.7 M undefined |
| 2019 | 64.2 M undefined | -177.2 M undefined | -151.8 M undefined |
| 2018 | 60.1 M undefined | -171.2 M undefined | -171.5 M undefined |
| 2017 | 157.7 M undefined | -22.1 M undefined | -19.6 M undefined |
| 2016 | 91.9 M undefined | -60 M undefined | -58.5 M undefined |
| 2015 | 100.9 M undefined | -20.2 M undefined | -20.1 M undefined |
| 2014 | 47.8 M undefined | -38.3 M undefined | -38.3 M undefined |
| 2013 | 58 M undefined | 400,000 undefined | -300,000 undefined |
| 2012 | 63.8 M undefined | 8.2 M undefined | 8.4 M undefined |
| 2011 | 57.2 M undefined | 5.2 M undefined | 6.7 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 57.2 M USD | 5.2 M USD | 6.7 M USD |
| 2012 | 63.8 M USD | 8.2 M USD | 8.4 M USD |
| 2013 | 58 M USD | 400,000 USD | -300,000 USD |
| 2014 | 47.8 M USD | -38.3 M USD | -38.3 M USD |
| 2015 | 100.9 M USD | -20.2 M USD | -20.1 M USD |
| 2016 | 91.9 M USD | -60 M USD | -58.5 M USD |
| 2017 | 157.7 M USD | -22.1 M USD | -19.6 M USD |
| 2018 | 60.1 M USD | -171.2 M USD | -171.5 M USD |
| 2019 | 64.2 M USD | -177.2 M USD | -151.8 M USD |
| 2020 | 104.9 M USD | -131.1 M USD | -129.7 M USD |
| 2021 | 77.4 M USD | -202.8 M USD | -202.1 M USD |
| 2022 | 151.9 M USD | -121.4 M USD | -119.8 M USD |
| 2023 | 58.75 M USD | -168.24 M USD | -9.06 M USD |
| 2024e | 123.71 M USD | -177.12 M USD | -139.86 M USD |
| 2025e | 89.46 M USD | -169.75 M USD | -162.91 M USD |
| 2026e | 94.25 M USD | -187.88 M USD | -132.43 M USD |
| 2027e | 88.94 M USD | -239.63 M USD | -109.4 M USD |
| 2028e | 164.14 M USD | -158.37 M USD | -95.96 M USD |
| 2029e | 342.21 M USD | 0 USD | 13.43 M USD |
MacroGenics stock margins US5560991094 · A1W6ND
The MacroGenics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MacroGenics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MacroGenics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the MacroGenics's sales revenue. A higher gross margin percentage indicates that the MacroGenics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the MacroGenics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the MacroGenics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MacroGenics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MacroGenics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MacroGenics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
MacroGenics Margin History
| MacroGenics Gross margin | MacroGenics Profit margin | MacroGenics EBIT margin | MacroGenics Profit margin |
|---|---|---|---|
| 2029e | 86 % | 0 % | 3.93 % |
| 2028e | 86 % | -96.48 % | -58.46 % |
| 2027e | 86 % | -269.43 % | -123 % |
| 2026e | 86 % | -199.33 % | -140.5 % |
| 2025e | 86 % | -189.74 % | -182.09 % |
| 2024e | 86 % | -143.17 % | -113.05 % |
| 2023 | 86 % | -286.38 % | -15.42 % |
| 2022 | 95.19 % | -79.92 % | -78.87 % |
| 2021 | 96.64 % | -262.02 % | -261.11 % |
| 2020 | 86 % | -124.98 % | -123.64 % |
| 2019 | 86 % | -276.01 % | -236.45 % |
| 2018 | 86 % | -284.86 % | -285.36 % |
| 2017 | 86 % | -14.01 % | -12.43 % |
| 2016 | 86 % | -65.29 % | -63.66 % |
| 2015 | 86 % | -20.02 % | -19.92 % |
| 2014 | 86 % | -80.13 % | -80.13 % |
| 2013 | 86 % | 0.69 % | -0.52 % |
| 2012 | 86 % | 12.85 % | 13.17 % |
| 2011 | 86 % | 9.09 % | 11.71 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | 86 % | 9.09 % | 11.71 % |
| 2012 | 86 % | 12.85 % | 13.17 % |
| 2013 | 86 % | 0.69 % | -0.52 % |
| 2014 | 86 % | -80.13 % | -80.13 % |
| 2015 | 86 % | -20.02 % | -19.92 % |
| 2016 | 86 % | -65.29 % | -63.66 % |
| 2017 | 86 % | -14.01 % | -12.43 % |
| 2018 | 86 % | -284.86 % | -285.36 % |
| 2019 | 86 % | -276.01 % | -236.45 % |
| 2020 | 86 % | -124.98 % | -123.64 % |
| 2021 | 96.64 % | -262.02 % | -261.11 % |
| 2022 | 95.19 % | -79.92 % | -78.87 % |
| 2023 | 86 % | -286.38 % | -15.42 % |
| 2024e | 86 % | -143.17 % | -113.05 % |
| 2025e | 86 % | -189.74 % | -182.09 % |
| 2026e | 86 % | -199.33 % | -140.5 % |
| 2027e | 86 % | -269.43 % | -123 % |
| 2028e | 86 % | -96.48 % | -58.46 % |
| 2029e | 86 % | 0 % | 3.93 % |
MacroGenics Aktienanalyse
What does MacroGenics do?
MacroGenics Inc is a biotechnology company that was founded in 2000 and is headquartered in Rockville, Maryland, USA. The company specializes in the research, development, and commercialization of therapeutic antibodies used in the treatment of cancer and autoimmune diseases. MacroGenics' business model is based on the production of different antibodies that primarily target various cell types and thereby elicit a targeted response. The company relies on a balanced approach to research and development to preferentially identify cellular markers that are characteristic of certain diseases, allowing for the identification of specific target molecules for antibody development. These innovative therapies lead to an improvement in the quality of life for patients by curing or at least managing severe diseases. Over the years, MacroGenics has built several divisions, including: Antibody platform technologies MacroGenics utilizes its proprietary platform technology for phage display and antibody manufacturing (Digitalis), as well as for the discovery of target molecules responsible for specific diseases. These technologies are used to identify new therapeutic antibody candidates and support the entire antibody development process. Cancer research and development MacroGenics is a pioneer in the development of innovative cancer therapies. One of the key products in this area is the antibody-based cancer drug Margetuximab, used for the treatment of metastatic breast cancer. Another promising drug in clinical phases is MGD019, which is highly effective for tumor treatment in the solid area. Autoimmune research and development MacroGenics is a leading developer of Neuromyelitis Optica Spectrum Disorder (NMOSD), which leads to recurring inflammation of the central nervous system. Additional products in the pipeline are being developed for the treatment of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, as there is still a wide range of needs in this field. Polyclonals and biosimilars This area includes the production of antibody polypeptides and biosimilar drugs. Antibody polypeptides can be used to treat infectious diseases or diagnose diseases. Biosimilar drugs are biological drugs that have similar active ingredients to other already approved drugs and are approved by the US Food and Drug Administration (FDA). These drugs are also known as generic replicas. MacroGenics' products have proven to be safe and effective in clinical trials. The company has established an extensive network of collaborations to market and distribute its products. Partners include major pharmaceutical companies such as Pfizer, Servier, and Janssen Biotech. Overall, MacroGenics has over 20 product pipelines in various stages of development and is constantly working to expand its product pipelines. The company employs over 400 employees and aims to revolutionize the treatment of severe and life-threatening diseases. In conclusion, MacroGenics Inc is an innovative biotechnology company that has developed and designed a variety of products for the treatment of cancer and autoimmune diseases. The company has a wide range of proprietary platform technologies and is constantly striving to expand its product pipelines. We expect the company to continue growing in the coming years and harness its innovative power to further benefit patients. MacroGenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding MacroGenics's Sales Figures
The sales figures of MacroGenics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing MacroGenics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize MacroGenics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in MacroGenics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about MacroGenics stock
How much was the turnover of the company MacroGenics compared to the previous year?
The revenue of MacroGenics has increased by 110.57% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of MacroGenics?
The revenue of MacroGenics is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of MacroGenics measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of MacroGenics so important for investors?
The revenue of MacroGenics is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does MacroGenics pay?
Over the past 12 months, MacroGenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MacroGenics is expected to pay a dividend of 0 USD.
What is the dividend yield of MacroGenics?
The current dividend yield of MacroGenics is .
When does MacroGenics pay dividends?
MacroGenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MacroGenics?
MacroGenics paid dividends every year for the past 0 years.
What is the dividend of MacroGenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MacroGenics located?
MacroGenics is assigned to the 'Health' sector.
Wann musste ich die Aktien von MacroGenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MacroGenics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did MacroGenics pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of MacroGenics in the year 2023?
In the year 2023, MacroGenics distributed 0 USD as dividends.
In which currency does MacroGenics pay out the dividend?
The dividends of MacroGenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The MacroGenics stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von MacroGenics
Our stock analysis for MacroGenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MacroGenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
